BioLargo is pleased to welcome a new member to our team, Julian Bejarano, PhD, who will hold the position of Director of Product Development at Clyra Medical Technologies. Julian will work closely with our leadership group to help create and refine new medical products under the umbrella of our Clyra advanced wound care product line. As Director of Product Development for Clyra, Julian will be responsible for bringing health care products to market from concept to commercialization. He will use the patented antimicrobial technology owned by Clyra to develop new products and formulas for dental applications, skin care, wound healing, skin regeneration, and bone replacement procedures, as well as other relevant products related to the healthcare field. Dr. Bejarano will evaluate nanoencapsulation approaches to boost the efficacy of active agents and improve the biocompatibility and physical features of the final product. He will also lead the planning, design and execution of studies to provide proof of concept, safety, and efficacy depending on the regulatory pathway of product development. We are very excited about the value he will add to Clyra and the entire company.
Julian is an expert scientific researcher with more than 11 years of experience leading fundamental and applied research projects related to materials science and nanotechnology. In particular, he has six years of experience in projects related to biomaterials for regenerative medicine and multifunctional nanoparticles for controlled drug delivery. Julian holds a Materials Engineering degree and a Masters in Materials Engineering from the Universidad del Valle, Colombia. He also holds a PhD in Engineering Sciences with emphasis in Materials Science from the Universidad de Chile, Chile. Julian was a visiting researcher during his PhD studies at the Institute of Biomaterials at the University of Erlangen-Nuremberg, Germany. Following his doctorate studies, Dr. Bejarano was a postdoctoral fellow at the Advanced Center for Chronic Diseases in Chile for three years and Research Advisor for the Group of Polymer Engineering at the Universidad de Chile. Moreover, he has outstanding skills in project management, R&D, and innovation. His projects have been focused on the development and characterization of composites materials based on metals, polymers and ceramics, synthesis of multifunctional nanoparticles, encapsulation of therapeutic agents, and biological evaluation of materials. His findings in materials research have been published by prestigious international journals and he has presented at several international events related to biomaterials and materials science.
Steve Harrison, President of Clyra Medical Technologies commented, “Julian brings unique and highly specialized knowledge and talent to the company. He will play an important role in helping us expand our product portfolio as we gear up for our commercial launch.”
What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.